A Q-TWiST Analysis Comparing Nivolumab and Therapy of Investigator’s Choice in Patients with Recurrent/Metastatic Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-2027
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
A Q-TWiST Analysis Comparing Nivolumab and Therapy of Investigator’s Choice in Patients with Recurrent/Metastatic Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck ; day:10 ; month:4 ; year:2019 ; pages:1-7
PharmacoEconomics ; (10.4.2019), 1-7
- Creator
-
Cocks, Kim
Contente, Marta
Simpson, Sarah
DeRosa, Michael
Taylor, Fiona C.
Shaw, James W.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40273-019-00798-1
- URN
-
urn:nbn:de:101:1-2019042823082739557525
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:51 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Cocks, Kim
- Contente, Marta
- Simpson, Sarah
- DeRosa, Michael
- Taylor, Fiona C.
- Shaw, James W.
- SpringerLink (Online service)
Other Objects (12)
Successful Treatment of Refractory Squamous Cell Cancer of the Head and Neck with Nivolumab and Ipilimumab
Nivolumab for Metastatic Cutaneous Squamous Cell Carcinoma
Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma
Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma
An exceptional response to nivolumab in relapsed and refractory malignant mesothelioma
Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report
Nivolumab-Induced Impressive Response of Refractory Pulmonary Sarcomatoid Carcinoma with Brain Metastasis
Clio Browne : Pribate Investigator
Young Investigator Award – Abstracts
Immunological effects of nivolumab immunotherapy in patients with oral cavity squamous cell carcinoma
Guide for investigator initiated trials
EFSUMB Young Investigator Award 2019
Successful Treatment of Refractory Squamous Cell Cancer of the Head and Neck with Nivolumab and Ipilimumab
Nivolumab for Metastatic Cutaneous Squamous Cell Carcinoma
Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma
Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma
An exceptional response to nivolumab in relapsed and refractory malignant mesothelioma
Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report
Nivolumab-Induced Impressive Response of Refractory Pulmonary Sarcomatoid Carcinoma with Brain Metastasis
Clio Browne : Pribate Investigator
Young Investigator Award – Abstracts
Immunological effects of nivolumab immunotherapy in patients with oral cavity squamous cell carcinoma
Guide for investigator initiated trials
EFSUMB Young Investigator Award 2019
Successful Treatment of Refractory Squamous Cell Cancer of the Head and Neck with Nivolumab and Ipilimumab
Nivolumab for Metastatic Cutaneous Squamous Cell Carcinoma
Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma
Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma
An exceptional response to nivolumab in relapsed and refractory malignant mesothelioma
Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report
Nivolumab-Induced Impressive Response of Refractory Pulmonary Sarcomatoid Carcinoma with Brain Metastasis
Clio Browne : Pribate Investigator
Young Investigator Award – Abstracts
Immunological effects of nivolumab immunotherapy in patients with oral cavity squamous cell carcinoma
Guide for investigator initiated trials